These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23960061)

  • 21. Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity.
    Patel RD; Blair MP; Shapiro MJ; Lichtenstein SJ
    Arch Ophthalmol; 2012 Jun; 130(6):801-2. PubMed ID: 22801851
    [No Abstract]   [Full Text] [Related]  

  • 22. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.
    Kim J; Kim SJ; Chang YS; Park WS
    Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bevacizumab (avastin) for the treatment of retinopathy of prematurity.
    Beaulieu MJ
    Neonatal Netw; 2012; 31(4):242-7. PubMed ID: 22763251
    [No Abstract]   [Full Text] [Related]  

  • 24. Intravitreal bevacizumab for exudative retinal detachment post laser therapy for retinopathy of prematurity.
    Ehmann D; Greve M
    Can J Ophthalmol; 2014 Apr; 49(2):228-31. PubMed ID: 24767234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravitreal Bevacizumab for Retinopathy of Prematurity: Another Hit to the Immature Lung?
    Oulego-Erroz I; Alonso-Ojembarrena A
    Chest; 2022 Dec; 162(6):1231-1232. PubMed ID: 36494122
    [No Abstract]   [Full Text] [Related]  

  • 26. Management of retinopathy of prematurity.
    Fleck BW
    Arch Dis Child Fetal Neonatal Ed; 2013 Sep; 98(5):F454-6. PubMed ID: 23813885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin).
    Dorta P; Kychenthal A
    Retina; 2010 Apr; 30(4 Suppl):S24-31. PubMed ID: 20224475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bevacizumab for retinopathy of prematurity.
    Gole GA; Camuglia JE; Ells AL
    N Engl J Med; 2011 Jun; 364(24):2360-1; author reply 2362. PubMed ID: 21675896
    [No Abstract]   [Full Text] [Related]  

  • 29. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up.
    Martínez-Castellanos MA; Schwartz S; Hernández-Rojas ML; Kon-Jara VA; García-Aguirre G; Guerrero-Naranjo JL; Chan RV; Quiroz-Mercado H
    Retina; 2013 Feb; 33(2):329-38. PubMed ID: 23099498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comment on "Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity".
    Er H
    Retina; 2009 Oct; 29(9):1380; author reply 1379-80. PubMed ID: 19934833
    [No Abstract]   [Full Text] [Related]  

  • 31. Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab.
    Ittiara S; Blair MP; Shapiro MJ; Lichtenstein SJ
    J AAPOS; 2013 Jun; 17(3):323-5. PubMed ID: 23607977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity.
    Suk KK; Berrocal AM; Murray TG; Rich R; Major JC; Hess D; Johnson RA
    J Pediatr Ophthalmol Strabismus; 2010 Dec; 47 Online():e1-4. PubMed ID: 21175113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravitreal bevacizumab for retinopathy of prematurity: Considerations for informed consent.
    Mireskandari K; Collins ME; Tehrani N
    Can J Ophthalmol; 2015 Dec; 50(6):409-12. PubMed ID: 26651298
    [No Abstract]   [Full Text] [Related]  

  • 34. Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years.
    Klufas MA; Chan RV
    J Pediatr Ophthalmol Strabismus; 2015; 52(2):77-84. PubMed ID: 25798707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
    Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
    Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Avastin as monotherapy for retinopathy of prematurity.
    Mintz-Hittner HA
    J AAPOS; 2010 Feb; 14(1):2-3. PubMed ID: 20227612
    [No Abstract]   [Full Text] [Related]  

  • 37. Bevacizumab for retinopathy of prematurity.
    Good WV; Palmer EA
    N Engl J Med; 2011 Jun; 364(24):2359; author reply 2361-2. PubMed ID: 21675899
    [No Abstract]   [Full Text] [Related]  

  • 38. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.
    Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB
    Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.
    Wu WC; Lien R; Liao PJ; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
    JAMA Ophthalmol; 2015 Apr; 133(4):391-7. PubMed ID: 25569026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity.
    Zepeda-Romero LC; Liera-Garcia JA; Gutiérrez-Padilla JA; Valtierra-Santiago CI; Avila-Gómez CD
    Eye (Lond); 2010 May; 24(5):931-3. PubMed ID: 19557020
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.